224 related articles for article (PubMed ID: 26914542)
1. A randomized, prospective comparison of transition to sirolimus-based CNI-minimization or withdrawal in African American kidney transplant recipients.
Fleming JN; Taber DJ; Pilch NA; McGillicuddy JW; Srinivas TR; Baliga PK; Chavin KD; Bratton CF
Clin Transplant; 2016 May; 30(5):528-33. PubMed ID: 26914542
[TBL] [Abstract][Full Text] [Related]
2. Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.
Karpe KM; Talaulikar GS; Walters GD
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD006750. PubMed ID: 28730648
[TBL] [Abstract][Full Text] [Related]
3. Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen.
Chhabra D; Alvarado A; Dalal P; Leventhal J; Wang C; Sustento-Reodica N; Najafian N; Skaro A; Levitsky J; Mas V; Gallon L
Am J Transplant; 2013 Nov; 13(11):2902-11. PubMed ID: 24007570
[TBL] [Abstract][Full Text] [Related]
4. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
Flechner SM; Kobashigawa J; Klintmalm G
Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
[TBL] [Abstract][Full Text] [Related]
5. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study.
Uchida J; Machida Y; Iwai T; Kuwabara N; Kabei K; Naganuma T; Kumada N; Kawashima H; Nakatani T
Clin Transplant; 2014 Jan; 28(1):80-7. PubMed ID: 24329776
[TBL] [Abstract][Full Text] [Related]
6. Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis.
Su L; Tam N; Deng R; Chen P; Li H; Wu L
Int Urol Nephrol; 2014 Oct; 46(10):2035-44. PubMed ID: 25027805
[TBL] [Abstract][Full Text] [Related]
7. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.
Hahn D; Hodson EM; Hamiwka LA; Lee VW; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD004290. PubMed ID: 31840244
[TBL] [Abstract][Full Text] [Related]
8. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.
Berger SP; Sommerer C; Witzke O; Tedesco H; Chadban S; Mulgaonkar S; Qazi Y; de Fijter JW; Oppenheimer F; Cruzado JM; Watarai Y; Massari P; Legendre C; Citterio F; Henry M; Srinivas TR; Vincenti F; Gutierrez MPH; Marti AM; Bernhardt P; Pascual J;
Am J Transplant; 2019 Nov; 19(11):3018-3034. PubMed ID: 31152476
[TBL] [Abstract][Full Text] [Related]
9. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Three-Year Results From the Randomized SCHEDULE Study.
Andreassen AK; Andersson B; Gustafsson F; Eiskjaer H; Rådegran G; Gude E; Jansson K; Solbu D; Karason K; Arora S; Dellgren G; Gullestad L;
Am J Transplant; 2016 Apr; 16(4):1238-47. PubMed ID: 26820618
[TBL] [Abstract][Full Text] [Related]
10. Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy.
Sommerer C; Duerr M; Witzke O; Lehner F; Arns W; Kliem V; Ackermann D; Guba M; Jacobi J; Hauser IA; Stahl R; Reinke P; Rath T; Veit J; Mehrabi A; Porstner M; Budde K;
Am J Transplant; 2018 Dec; 18(12):2965-2976. PubMed ID: 29722128
[TBL] [Abstract][Full Text] [Related]
11. Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study.
Budde K; Rath T; Sommerer C; Haller H; Reinke P; Witzke O; Suwelack B; Baeumer D; May C; Porstner M; Arns W
Clin Nephrol; 2015 Jan; 83(1):11-21. PubMed ID: 25512099
[TBL] [Abstract][Full Text] [Related]
12. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
[TBL] [Abstract][Full Text] [Related]
13. Randomized Sirolimus-based Early Calcineurin Inhibitor Reduction in Liver Transplantation: Impact on Renal Function.
Buchholz BM; Ferguson JW; Schnitzbauer AA; Nightingale P; Schlitt HJ; Geissler EK; Mirza DF;
Transplantation; 2020 May; 104(5):1003-1018. PubMed ID: 31577671
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure.
Groetzner J; Kaczmarek I; Schulz U; Stegemann E; Kaiser K; Wittwer T; Schirmer J; Voss M; Strauch J; Wahlers T; Sohn HY; Wagner F; Tenderich G; Stempfle HU; Mueller-Ehmsen J; Schmid C; Vogeser M; Koch KC; Reichenspurner H; Daebritz S; Meiser B; Reichart B;
Transplantation; 2009 Mar; 87(5):726-33. PubMed ID: 19295318
[TBL] [Abstract][Full Text] [Related]
15. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
Flechner SM; Goldfarb D; Solez K; Modlin CS; Mastroianni B; Savas K; Babineau D; Kurian S; Salomon D; Novick AC; Cook DJ
Transplantation; 2007 Apr; 83(7):883-92. PubMed ID: 17460558
[TBL] [Abstract][Full Text] [Related]
16. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation.
Knight RJ; Podder H; Kerman RH; Lawless A; Katz SM; Van Buren CT; Gaber AO; Kahan BD
Transplantation; 2010 Mar; 89(6):727-32. PubMed ID: 20195219
[TBL] [Abstract][Full Text] [Related]
17. Calcineurin inhibitor sparing immunosuppressive regimens in kidney allograft recipients.
Baczkowska T; Durlik M
Pol Arch Med Wewn; 2009 May; 119(5):318-25. PubMed ID: 19579814
[TBL] [Abstract][Full Text] [Related]
18. Renal function improvement after conversion to proliferation signal inhibitors during long-term follow-up in heart transplant recipients.
Kaplinsky E; González-Costello J; Manito N; Roca J; Barbosa MJ; Nebot M; Salazar-Mendiguchia J; Berdejo J; Mañas P; Miralles A; Cequier A
Transplant Proc; 2012 Nov; 44(9):2564-6. PubMed ID: 23146455
[TBL] [Abstract][Full Text] [Related]
19. Calcineurin inhibitor avoidance and withdrawal for kidney transplantation: a systematic review and meta-analysis of randomized controlled trials.
Yan HL; Zong HT; Cui YS; Li N; Zhang Y
Transplant Proc; 2014 Jun; 46(5):1302-13. PubMed ID: 24935293
[TBL] [Abstract][Full Text] [Related]
20. Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus.
Mandelbrot DA; Alberú J; Barama A; Marder BA; Silva HT; Flechner SM; Flynn A; Healy C; Li H; Tortorici MA; Schulman SL
Am J Transplant; 2015 Dec; 15(12):3174-84. PubMed ID: 26176342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]